ScreenerHero

ENLV Enlivex Ltd.

NAS · US · Healthcare · Biotechnology · enlivex.com
0.3064USD-9.94%Mkt Cap: 6.10M $P/E: 0.00

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as we…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.10M USD
Enterprise Value17.75M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)1.24B USD
Revenue/Share—
Last Price0.3064 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.44
PEG—
EV/EBITDA-0.74
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)462.83
EPS (Forward)-0.78
52W Range
0.30000% of range27.15
52W High27.15 USD
52W Low0.3000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE63.85%
ROA53.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.42M USD
CapEx (TTM)68.00K USD
FCF Margin—
FCF Yield-61302.48%
Net Debt12.03M USD
Net Debt/EBITDA-0.50
Balance Sheet
Debt/Equity0.00
Current Ratio119.39
Quick Ratio0.18
Book Value/Sh231.60 USD
Cash/Share0.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 6, 2019
Splits
Last Split1:15
Split DateJul 9, 2026
Analyst Consensus
Rating—
Target (Mean)80.00 USD
Upside (mean)+26009.7%
Target Range80.00 USD – 80.00 USD
# Analysts1
Ownership
Shares Out.19.91M
Float6.55M
Insiders68.82%
Institutions1.42%
Short Interest
Short Ratio0.2d
Short % Float0.28%
Short % Out.0.28%
Shares Short48.20K
Short (prev mo.)104.20K
Technical
SMA 501.353 (-77.3%)
SMA 2009.851 (-96.9%)
Beta1.41
S&P 52W Chg16.45%
Avg Vol (30d)433.84K
Avg Vol (10d)651.39K
Technical Indicators
RSI (14)10.7
MACD-0.4126
MACD Signal-0.4727
MACD Hist.+0.0601
BB Upper1.157 USD
BB Middle0.6571 USD
BB Lower0.1574 USD
BB Width152.09%
ATR (14)0.1306 USD
Vol Ratio (20d)1.69x